Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

The goal of this observational study is to learn if a specific diabetes medicine can lower the risk of lung cancer in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: \- Does taking medicines called SGLT2 inhibitors lower the chance of getting lung cancer compared to medicines called sulfonylureas? Researchers will compare the medical records of people taking SGLT2 inhibitors to those taking sulfonylureas to see if the SGLT2 group has fewer cases of lung cancer. Participants will not need to visit a doctor or take new medicines for this study. Researchers will use information from existing medical records to answer the research question.

NCT Number	NCT07332156
Lead Sponsor	Samsung Medical Center
Conditions	Type 2 Diabetes, COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis)
Enrollment	21,692 participants
Start Date	2009-01-01
Primary Completion	2023-12-31 (estimated)
Study Completion	2023-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-14